<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20356">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02841891</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-106-0129</org_study_id>
    <nct_id>NCT02841891</nct_id>
  </id_info>
  <brief_title>A Clinical Study Comparing Standard Anastomosis Closure Technique to Standard Closure Techniques Plus Sylys® Surgical Sealant</brief_title>
  <official_title>A Pilot, Prospective, Randomized, Controlled, Multicenter Technical Feasibility Clinical Study Comparing Standard Anastomosis Closure Technique to Standard Closure Techniques Plus Sylys® Surgical Sealant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cohera Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cohera Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Cohera Sylys® Surgical Sealant study is a prospective, randomized, controlled,
      multicenter technical feasibility clinical study comparing standard anastomosis closure
      technique (Control) to standard closure techniques plus Sylys® Surgical Sealant (Test)
      during colorectal and ileorectal anastomosis procedures.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Sylys Surgical Sealant: Number of Device Related Adverse Events</measure>
    <time_frame>6 Months</time_frame>
    <description>Number of participants with Device Related Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sealant Application Evaluation Questionnaire</measure>
    <time_frame>At time of device application (during surgery)</time_frame>
    <description>Questionnaire documenting the ability to apply the sealant adequately to the anastomosis line.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Colorectal and Ileorectal Anastomosis</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test group will receive Sylys Surgical Sealant as an adjunct to standard closure of colorectal or illeorectal anastomosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group will receive standard of care of colorectal or illeorectal anastomosis surgery with standard closure without Sylys Surgical Sealant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sylys Surgical Sealant</intervention_name>
    <description>Standard Colorectal or Illeorectal Anastomosis Surgical Procedure with the addition of Sylys Surgical Sealant</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Anastomosis Surgical Procedure</intervention_name>
    <description>Standard Colorectal or Illeorectal Anastomosis Surgical Procedure without the addition of Sylys Surgical Sealant</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 22 years of age

          -  Be scheduled for a colorectal or ileorectal anastomosis procedure with a diverting
             stoma

          -  Agree to return for all follow-up evaluations and procedures specified in the
             protocol

          -  Understand and give informed consent

        Exclusion Criteria:

          -  Albumin &lt; 3 g/dL

          -  ASA score (American Society of Anesthesiologists) ≥ 4

          -  Neutropenia ≤ 800 cells/μl

          -  Pregnancy

          -  The following conditions involving compromised immune system: AIDS (HIV positive not
             excluded), neutropenia

          -  Known blood clotting disorder requiring treatment

          -  Have known or suspected allergy or sensitivity to any test materials or reagents

          -  Concurrent use of fibrin sealants or other anastomosis care devices

          -  Surgery for emergency abdominal indications

          -  Patients who have undergone prior colorectal anastomosis surgery in the previous two
             months, or are receiving an additional anastomosis related to complications from a
             previous anastomosis procedure

          -  Stage 1 (First 20 patients) Only (High Risk Cancer Patients):

          -  Lymph Node Cancer Stage: N2

          -  Cancer Tumor Size: T4

          -  Circumferential resection margin: CRM+ (Positive)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chad Coberly, JD</last_name>
    <phone>984-222-0400</phone>
    <email>ccoberly@coheramed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessio Pigazzi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amit Merchea, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Margolin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Larson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Denoya, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie Thacker, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katerina Wells, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Moesinger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univeristy of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bartley Pickron, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>July 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
